Search results for "stroke."

showing 10 items of 1178 documents

Clot Composition Analysis as a Diagnostic Tool to Gain Insight into Ischemic Stroke Etiology: A Systematic Review

2021

Mechanical thrombectomy renders the occluding clot available for analysis. Insights into thrombus composition could help establish the stroke cause. We aimed to investigate the value of clot composition analysis as a complementary diagnostic tool in determining the etiology of large vessel occlusion (LVO) ischemic strokes (International Prospective Register of Systematic Reviews [PROSPERO] registration # CRD42020199436). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we ran searches on Medline (using the PubMed interface) and Web of Science for studies reporting analyses of thrombi retrieved from LVO stroke patients subjected to mechani…

medicine.medical_specialtyetiologyMEDLINEReviewComposition analysiscerebral thrombusCerebral thrombus Etiology Ischemic stroke Systematic review ThrombectomyEmbolussystematic reviewischemic strokeMedicineDiseases of the circulatory (Cardiovascular) systemcardiovascular diseasesThrombusIntensive care medicineStrokebusiness.industrymedicine.diseaseSystematic reviewthrombectomyRC666-701EtiologyNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessCohort studyJournal of Stroke
researchProduct

Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis

2021

Abstract Aims Cardiac resynchronization therapy (CRT) is highly effective in dilated cardiomyopathy (DCM) patients with impaired left ventricular ejection fraction (LVEF) and left bundle block branch. In cardiac amyloidosis (CA) patients, left ventricular dysfunction and conduction defects are common, but the potential of CRT to improve cardiac remodelling and survival in this particular setting remains undefined. We investigated cardiovascular outcomes in CA patients after CRT implantation in terms of CRT echocardiographic response and major cardiovascular events (MACEs). Methods and results Our retrospective study included 47 CA patients implanted with CRT devices from January 2012 to Feb…

medicine.medical_specialtygenetic structuresmedicine.medical_treatmentPopulationCardiac resynchronization therapyHeart failureCardiac amyloidosisVentricular Function LeftInternal medicineImplantable cardioverter defibrillatormedicineHumansDiseases of the circulatory (Cardiovascular) systemcardiovascular diseaseseducationAgedRetrospective StudiesAged 80 and overeducation.field_of_studyCardiac resynchronization therapyEjection fractionbusiness.industryHazard ratioDilated cardiomyopathyStroke VolumeOriginal ArticlesAmyloidosismedicine.diseaseImplantable cardioverter-defibrillatorDefibrillators ImplantablePacemakerTreatment OutcomeCardiac amyloidosisHeart failureRC666-701Cardiologycardiovascular systemOriginal ArticleCardiology and Cardiovascular Medicinebusinesstherapeuticscirculatory and respiratory physiologyESC Heart Failure
researchProduct

Obstructive Sleep Apnea and the Brain

2018

medicine.medical_specialtyinsomniabrainlcsh:Surgerymultiple sclerosis03 medical and health sciences0302 clinical medicineInternal medicineInsomniaMedicineStrokesleep disruptionneurobehaviouralbusiness.industryMultiple sclerosisSleep apnealcsh:RD1-811medicine.diseasesleep apneastrokeObstructive sleep apneaEditorialfemale030228 respiratory systemCardiologySurgerymedicine.symptombusiness030217 neurology & neurosurgeryFrontiers in Surgery
researchProduct

Rehospitalization burden and morbidity risk in patients with heart failure with mid-range ejection fraction

2020

Aims Heart failure with mid-range ejection fraction (HFmrEF) has been proposed as a distinct HF phenotype, but whether patients on this category fare worse, similarly, or better than those with HF with reduced EF (HFrEF) or preserved EF (HFpEF) in terms of rehospitalization risks over time remains unclear. Methods and results We prospectively included 2961 consecutive patients admitted for acute HF (AHF) in our institution. Of them, 158 patients died during the index admission, leaving the sample size to be 2803 patients. Patients were categorized according to their EF: HFrEF if EF ≤ 40% (n = 908, 32.4%); HFmrEF if EF = 41–49% (n = 449, 16.0%); and HFpEF if EF ≥ 50% (n = 1446, 51.6%). Covar…

medicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemHeart failure030204 cardiovascular system & hematologyRecurrent events03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineCause of DeathOriginal Research ArticlesmedicineHumansIn patient030212 general & internal medicineRegistriesOriginal Research ArticleHeart FailureEjection fractionbusiness.industryMorbidity riskIncidenceHeart failure with mid-range ejection fractionStroke VolumeHeart failure with mid‐range ejection fractionmedicine.diseasePrognosisConfidence intervalReadmissionslcsh:RC666-701Heart failureCardiologyCardiology and Cardiovascular Medicinebusiness
researchProduct

Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial

2020

AbstractPatients with stroke or transient ischemic attacks (TIAs) and internal carotid artery stenosis harbor an increased risk of recurrent stroke especially within 2 weeks after the first event. In addition, the revascularization procedure itself (carotid endarterectomy [CEA] or carotid artery stenting [CAS]) is associated with both clinically apparent and silent brain infarctions, mainly caused by the embolic nature of the ruptured carotid plaque. The glycoprotein VI (GPVI) fusion protein Revacept is a highly specific antithrombotic drug without direct inhibition of systemic platelet function that might reduce periprocedural distal embolization from the vulnerable ruptured plaque located…

medicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_treatmentCarotid endarterectomy030204 cardiovascular system & hematologyplatelet inhibitorRevascularization03 medical and health sciences0302 clinical medicineInternal medicinemedicine.arteryAntithromboticmedicineMyocardial infarctioncardiovascular diseasesStroke030304 developmental biologyrevacept0303 health sciencesbusiness.industrymedicine.diseasestrokeTolerabilitylcsh:RC666-701Hemostasistransient ischemic attackCardiologycarotid stenosisOriginal ArticleInternal carotid arterybusinessTH Open
researchProduct

Cerebrovascular Brainstem Diseases with Isolated Cranial Nerve Palsies

2002

There is a significant number of individual patients with cranial nerve palsies as the sole manifestation of MRI- and, less frequently, CT-documented small brainstem infarctions or hemorrhages. The 3rd and 6th nerves are most commonly involved and, less frequently, the 4th, 5th, 7th, and 8th nerves. An intra-axial basis for such lesions may be underestimated if the diagnosis is based solely on MRI. The electrophysiologic abnormalities indicating brainstem lesions may be independent of MRI-documented morphological lesions. This paper reviews the literature on cerebrovascular brainstem diseases manifesting as isolated cranial nerve palsies. It supports the concept that small pontine and mesen…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryInfarctionMagnetic resonance imagingmedicine.diseaseMagnetic Resonance ImagingCranial Nerve DiseasesCerebrovascular DisordersNeurologyElderly populationInternal medicineAnesthesiamedicineCardiologyHumansNeurology (clinical)Corneal reflexBrainstemCardiology and Cardiovascular MedicinebusinessSmall brainstemStrokeJaw jerk reflexBrain StemCerebrovascular Diseases
researchProduct

Pathophysiologische Aspekte hirnstruktureller Veränderungen bei Morbus Fabry: Literaturübersicht

2006

Fabry Disease (FD) is a rare X-linked lysosomal storage disorder caused by deficiency of alpha-galactosidase A (alpha-GAL) enzyme activity. Neutral glycosphingolipides (esp. Gb3) accumulate in lysosomes of several tissues, particularly in vascular endothelium and smooth muscle cells. Cerebral manifestations that might be mainly due to progressive cerebrovascular dysfunction, are one major and often life-threatening burden of the disease. We reviewed the present literature concerning brain structural alterations in FD and discuss the possibly relevant underlying pathophysiological aspects of these disturbances. Cerebrovascular events (TIA, stroke) occur in FD at a rather early age. In female…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryPhysiologyMagnetic resonance imagingDiseaseEnzyme replacement therapymedicine.diseaseFabry diseaseHyperintensityAngiopathyPsychiatry and Mental healthNeurologyInternal medicinemedicineCardiologyNeurology (clinical)businessStrokePathologicalFortschritte der Neurologie · Psychiatrie
researchProduct

Functional MRI and motor behavioral changes obtained with constraint-induced movement therapy in chronic stroke

2011

Background:  The clinical benefits of intensive stroke rehabilitation vary individually. We used multimodal functional imaging to assess the relationship of clinical gain and imaging changes in patients with chronic stroke whose voluntary motor control improved after constraint-induced movement therapy (CIMT). Methods:  Eleven patients (37.6 ± 36.8 months from stroke) were studied by functional MRI (fMRI), transcranial magnetic stimulation (TMS), and behavioral assessment of hand motor control (Wolf Motor Function Test) before and after 2 weeks of CIMT. Individual and group-level changes in imaging and behavioral parameters were investigated. Results:  Increase in fMRI activation in the sen…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentMotor controlMagnetic resonance imagingmedicine.diseasebehavioral disciplines and activitiesBrain mappingConstraint-induced movement therapyFunctional imagingTranscranial magnetic stimulationPhysical medicine and rehabilitationNeurologyLateralitymedicineNeurology (clinical)businessStrokepsychological phenomena and processesEuropean Journal of Neurology
researchProduct

Letter by Barco et al Regarding Article, "Restarting Anticoagulant Therapy After Intracranial Hemorrhage: A Systematic Review and Meta-Analysis"

2017

We read with interest the systematic review and meta-analysis authored by Murthy et al1 that appeared in Stroke . The authors studied the efficacy and safety of anticoagulant resumption after nontraumatic intracranial hemorrhage (ICH) and showed that resumption was associated with a lower risk of arterial thromboembolism but a similar risk of recurrent ICH. We do have some comments on their interpretation of the results. First, all the included studies had a retrospective design and, therefore, are characterized by heterogeneity in treatment regimens and timing of anticoagulation restart. As the authors argue in their discussion, location matters for the risk of recurrent ICH: lobar bleedin…

medicine.medical_specialtymedicine.drug_class030204 cardiovascular system & hematologyLower risk03 medical and health sciences0302 clinical medicinemedicineHumanscardiovascular diseasesIntensive care medicineStrokeAdvanced and Specialized NursingHumans; Anticoagulants; Intracranial HemorrhagesTreatment regimenbusiness.industryAnticoagulantAnticoagulantsmedicine.diseaseCausalitynervous system diseasesSurgeryAnticoagulant therapyMeta-analysisNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessIntracranial Hemorrhages030217 neurology & neurosurgeryRetrospective design
researchProduct

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases

2020

Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for thrombolysis with recombinant tissue-type plasminogen activator (rt-PA). In patients on dabigatran with intracerebral hemorrhage idarucizumab could prevent lesion growth. Aims To provide insights into the clinical use of idarucizumab in patients under effective dabigatran anticoagulation presenting with signs of acute ischemic stroke or intracranial hemorrhage. Methods Retrospective data collected from German neurological/neurosurgical departments ad…

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentMedizinAntibodies Monoclonal HumanizedAntithrombinsBrain IschemiaDabigatranGermanyInternal medicinemedicineHumansThrombolytic Therapyddc:610Ischemic StrokeRetrospective StudiesIntracerebral hemorrhagebusiness.industryAnticoagulantWarfarinIdarucizumabAtrial fibrillationThrombolysisVitamin K antagonistmedicine.diseaseDabigatranStrokeNeurologyCardiologybusinessIntracranial Hemorrhagesmedicine.drugInternational Journal of Stroke
researchProduct